A
Austin L. Chien
Researcher at University of Pennsylvania
Publications - 9
Citations - 637
Austin L. Chien is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Pembrolizumab. The author has an hindex of 4, co-authored 7 publications receiving 357 citations.
Papers
More filters
Journal ArticleDOI
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Charu Aggarwal,Jeffrey C. Thompson,Taylor A. Black,Sharyn I. Katz,Ryan Fan,Stephanie S. Yee,Austin L. Chien,Tracey L. Evans,Joshua Bauml,Evan W. Alley,Christine Ciunci,Abigail T. Berman,Roger B. Cohen,David B. Lieberman,Krishna S. Majmundar,Samantha L. Savitch,Jennifer J.D. Morrissette,Wei-Ting Hwang,Kojo S.J. Elenitoba-Johnson,Corey J. Langer,Erica L. Carpenter +20 more
TL;DR: In this article, a prospective cohort study enrolled 323 patients with metastatic non-small cell lung cancer (NSCLC) who had plasma testing ordered as part of routine clinical management.
Journal ArticleDOI
Hepatocytes direct the formation of a pro-metastatic niche in the liver
Jae W. Lee,Meredith L. Stone,Paige M. Porrett,Stacy K. Thomas,Chad A. Komar,Joey H. Li,Devora Delman,Kathleen Graham,Whitney L. Gladney,Xia Hua,Taylor A. Black,Austin L. Chien,Krishna S. Majmundar,Jeffrey C. Thompson,Stephanie S. Yee,Mark H. O'Hara,Charu Aggarwal,Dong Xin,Abraham Shaked,Mingming Gao,Dexi Liu,Mitesh J. Borad,Ramesh K. Ramanathan,Ramesh K. Ramanathan,Erica L. Carpenter,Ailing Ji,Maria C. de Beer,Frederick C. de Beer,Nancy R. Webb,Gregory L. Beatty +29 more
TL;DR: It is shown that hepatocytes coordinate myeloid cell accumulation and fibrosis within the liver and, in doing so, increase the susceptibility of the liver to metastatic seeding and outgrowth.
Journal ArticleDOI
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Charu Aggarwal,Jeffrey C. Thompson,Austin L. Chien,Katie Quinn,Wei-Ting Hwang,Taylor A. Black,Stephanie S. Yee,Theresa Christensen,Michael J. LaRiviere,Benjamin A. Silva,Kimberly C. Banks,Rebecca J. Nagy,Elena Helman,Abigail T. Berman,Christine Ciunci,Aditi P. Singh,Jeffrey S. Wasser,Joshua Bauml,Corey J. Langer,Roger B. Cohen,Erica L. Carpenter +20 more
TL;DR: PTMB ≥ 16 mut/Mb is associated with improved PFS after first-line standard-of-care pembrolizumab-based therapy in mNSCLC and STK11/KEAP1/PTEN and ERBB2 mutations may help identify pTMB-high patients unlikely to respond.
Journal ArticleDOI
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
Jeffrey C. Thompson,Erica L. Carpenter,Benjamin A. Silva,Jamie Rosenstein,Austin L. Chien,Katie Quinn,Carin R. Espenschied,Allysia J. Mak,Lesli A. Kiedrowski,Martina I. Lefterova,Rebecca J. Nagy,Sharyn I. Katz,Stephanie S. Yee,Taylor A. Black,Aditi P. Singh,Christine Ciunci,Joshua Bauml,Roger B. Cohen,Corey J. Langer,Charu Aggarwal +19 more
TL;DR: Molecular response assessment using circulating tumor DNA may serve as a noninvasive, on-therapy predictor of response to pembrolizumab-based therapy in addition to standard of care imaging in mNSCLC.
Journal ArticleDOI
Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors.
Bardia Yousefi,Michael J. LaRiviere,Eric A. Cohen,Thomas H. Buckingham,Stephanie S. Yee,Taylor A. Black,Austin L. Chien,Peter B. Noël,Wei-Ting Hwang,Sharyn I. Katz,Charu Aggarwal,Jeffrey C. Thompson,Erica L. Carpenter,Despina Kontos +13 more
TL;DR: In this article, a single-center retrospective study included 40 EGFR-mutant advanced non-small cell lung cancer patients treated with EGFRtargeted therapy and showed that combining radiomic phenotypes, ctDNA, and clinical variables may enhance precision oncology approaches to manage advanced nonsmall cancer with EGF mutations.